Direkt zum Inhalt
Merck
  • Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review.

Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review.

Neonatology (2010-02-13)
Lex W Doyle, Richard A Ehrenkranz, Henry L Halliday
ZUSAMMENFASSUNG

Corticosteroids have been used widely after birth in preterm infants with respiratory failure; hydrocortisone may be preferable to other corticosteroids for this purpose. To determine if postnatal hydrocortisone is useful to prevent or treat bronchopulmonary dysplasia (BPD) in preterm infants. Randomised controlled trials (RCTs) of postnatal hydrocortisone therapy to prevent or treat BPD were sought. Data regarding clinical outcomes including mortality, BPD, death or BPD, complications during the primary hospitalisation, and long-term outcome were abstracted and analysed using RevMan 5. Eight RCTs enrolling a total of 880 participants were eligible. In all trials treatment was started in the first week of life; there were no trials of treatment started in infants who were chronically ventilator-dependent after the first week of life with established or evolving BPD. A meta-analysis of the available trials demonstrated little evidence for a direct effect of hydrocortisone on the rates of BPD, mortality, or the combined outcome of BPD or mortality. Hydrocortisone in the doses used in these eight studies had few beneficial or harmful effects; the notable exception was an increase in gastrointestinal perforation. Postnatal hydrocortisone in the doses and regimens used in the reported trials has few beneficial or harmful effects and cannot be recommended for prevention of BPD. There are no randomised trials to substantiate the use of hydrocortisone in chronically ventilator-dependent infants with established or evolving BPD.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Hydrocortison, BioReagent, suitable for cell culture
SKU
Packungsgröße
Verfügbarkeit
Preis
Menge
Sigma-Aldrich
Hydrocortison -Lösung, 50 μM, sterile-filtered, BioXtra, suitable for cell culture
SKU
Packungsgröße
Verfügbarkeit
Preis
Menge
Sigma-Aldrich
Hydrocortison, γ-irradiated, powder, BioXtra, suitable for cell culture
SKU
Packungsgröße
Verfügbarkeit
Preis
Menge
Sigma-Aldrich
Hydrocortison, ≥98% (HPLC)
SKU
Packungsgröße
Verfügbarkeit
Preis
Menge
Supelco
Cortisol -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
SKU
Packungsgröße
Verfügbarkeit
Preis
Menge
USP
Hydrocortison, United States Pharmacopeia (USP) Reference Standard
SKU
Packungsgröße
Verfügbarkeit
Preis
Menge
Sigma-Aldrich
Hydrocortison, meets USP testing specifications
SKU
Packungsgröße
Verfügbarkeit
Preis
Menge
Supelco
Hydrocortison, Pharmaceutical Secondary Standard; Certified Reference Material
SKU
Packungsgröße
Verfügbarkeit
Preis
Menge
Hydrocortison, European Pharmacopoeia (EP) Reference Standard
SKU
Packungsgröße
Verfügbarkeit
Preis
Menge
Hydrocortison für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
SKU
Packungsgröße
Verfügbarkeit
Preis
Menge